In the ongoing effort to find drugs that safely and effectively reduce cardiovascular events, there’s a new class of stars: PCSK9 inhibitors. These drugs are antibodies directed at the PCSK9 protein, which regulates LDL receptor recycling. Blocking the protein results in increasing the effective number of receptors, which leads to
Statins—taken by more than 25 million Americans to combat the high cholesterol levels that can harm cardiovascular health—are highly effective when it comes to lowering the risk for cardiovascular-related events and mortality. They also are low cost, and generally safe to take. However, for some people, statins come with side
Cholesterol-lowering statins are wonder drugs for reducing low-density lipoprotein (LDL, “bad”) cholesterol and lessening cardiovascular risk. Yet, a significant number of patients cannot tolerate the medications or fail to reach target LDL levels despite being on maximum-dose statin therapy.
Enter a new class of drugs—proprotein convertase subtilisin kexin type 9 (PCSK9)